Market Research Logo

Mild Cognitive Impairment - Pipeline Review, H2 2015

Mild Cognitive Impairment - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Mild cognitive impairment - Pipeline Review, H2 2015’, provides an overview of the Mild cognitive impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild cognitive impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild cognitive impairment and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mild cognitive impairment
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mild cognitive impairment and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mild cognitive impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mild cognitive impairment pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mild cognitive impairment
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mild cognitive impairment pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Mild Cognitive Impairment Overview
Therapeutics Development
Pipeline Products for Mild Cognitive Impairment - Overview
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis
Mild Cognitive Impairment - Therapeutics under Development by Companies
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
Mild Cognitive Impairment - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Mild Cognitive Impairment - Products under Development by Companies
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes
Mild Cognitive Impairment - Companies Involved in Therapeutics Development
Actinogen Limited
Avraham Pharmaceuticals Ltd.
Boehringer Ingelheim GmbH
CereSpir Incorporated
D-Pharm Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
Octapharma AG
Sage Therapeutics
Sanofi
Suven Life Sciences Ltd.
Mild Cognitive Impairment - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BAN-2401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCA-909 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSP-1103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DAOI-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-NDD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
insulin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ladostigil tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levetiracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY-3002813 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-228810 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-502 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-507 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-512 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVN-976 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SUVND-4010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tropisetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UE-2343 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mild Cognitive Impairment - Recent Pipeline Updates
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Discontinued Products
Mild Cognitive Impairment - Product Development Milestones
Featured News & Press Releases
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m
Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer’s Disease At ICAD 2009, Vienna, Austria.
Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland
Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Mild Cognitive Impairment, H2 2015
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Mild Cognitive Impairment - Pipeline by Actinogen Limited, H2 2015
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2015
Mild Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2015
Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H2 2015
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2015
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2015
Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2015
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, H2 2015
Mild Cognitive Impairment - Pipeline by Sanofi, H2 2015
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H2 2015
Mild Cognitive Impairment - Dormant Projects, H2 2015
Mild Cognitive Impairment - Dormant Projects (Contd..1), H2 2015
Mild Cognitive Impairment - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Mild Cognitive Impairment, H2 2015
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report